Cephalon Inc. v. Aurobindo Pharma Limited
1:15-cv-01044
Overview
Parties
Defendant
Aurobindo Pharma USA Inc. Operating Company
Represented By
0 Attorneys ListedAurobindo Pharma Limited NPE (University / Research)
Represented By
0 Attorneys ListedPlaintiff
Teva Sante S.A.S. Operating Company
Represented By
2 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Cephalon Inc. Operating Company
Represented By
2 Attorneys ListedFish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Fish & Richardson, P.C.
222 Delaware Avenue, 17th Floor, P.O. Box 1114
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 11 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 7,132,570 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 2006024132 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 9,382,200 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2010004871 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2010004872 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2009028119 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,729,305 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,975,442 B2 | US Continuation / Sibling | View Official Patent → |
| π«π· France | FR 0216412 | France Counterpart | View Official Patent → |
| π«π· France | FR 2849029 B1 | France Counterpart | View Official Patent → |
| π PCT International (WIPO) | WO 2004060858 A1 | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US7132570
Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil
|
Filed: 2003-12-18
Issued: 2006-11-07
|
Expired (Term Ended)
Expires: 2023-12-18
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term β No obviousness-type double patenting truncation noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th & 8th Year Maintenance Fees Paid (12th Year Window Upcoming).